{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI were not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI were not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Overall survival was defined as the time in days from randomization to the date of death, regardless of cause (date of death - date of randomization + 1).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to Pralatrexate Arm received pralatrexate as an intravenous (IV) push administered over a minimum of 30 seconds up to a maximum of 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride \\[NaCl\\]) weekly for 3 weeks of a 4-week cycle. Initial dose of pralatrexate was 30 milligram per meter square (mg/m\\^2), could be reduced to 20 mg/m\\^2 with potential further reductions to 15 and 10 mg/m\\^2 based on toxicity, along with vitamin B12, 1 milligram (mg) intramuscular (IM), every 8-10 weeks and folic acid 1-1.25 mg by mouth (po) once a day (qd) until a criterion for study treatment discontinuation was met or up to a maximum of 2 years.","id":"OG000","title":"Pralatrexate Arm"},{"description":"Participants randomized to Observation Arm received vitamin B12, 1 mg, IM every 8-10 weeks and folic acid 1-1.25 mg by mouth qd remained under observation, by attending clinic visits every 4 weeks, and being contacted by a healthcare professional during week 2 of every 4-week period until a criterion for study treatment discontinuation was met.","id":"OG001","title":"Observation Arm"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants classified according to the treatment arms into which they were randomized, regardless of the actual study treatment received (or not received).","reportingStatus":"POSTED","timeFrame":"From randomization until death (up to 76 months)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}